Literature DB >> 3774850

Platelet-activating factor (PAF-acether) induced leukotriene C4 formation and luminol dependent chemiluminescence by human eosinophils.

P L Bruynzeel, L Koenderman, P T Kok, M L Hameling, J Verhagen.   

Abstract

Human eosinophils are capable of synthesizing almost exclusively the strongly spasmogenic compound LTC4 when stimulated with either the calcium ionophore A 23187 or opsonized zymosan (OZ). Although PAF-acether in concentrations ranging from 10 nM to 1 microM is hardly capable of inducing significant LTC4 synthesis itself, it significantly enhances the OZ-induced LTC4 formation at a concentration of 1 microM. However, at a concentration of 10 microM, PAF-acether itself is capable of inducing LTC4 formation comparable with that induced by OZ. PAF-acether, at a concentration of 10 microM (and not at a concentration of 1 microM) is also capable of inducing a luminol dependent chemiluminescent response by eosinophils. The PAF-acether antagonist BN 52021 at a concentration of 0.1 mM not only partially inhibited the PAF-acether induced LTC4 formation but also the OZ induced LTC4 formation. Since an equal inhibition is found the inhibitory mode of action of BN 52021 is most likely directed towards a common pathway. Taken together, these results suggest that eosinophils may be triggered by high locally reached concentrations of PAF-acether to release inflammatory and bronchoconstrictive mediators. This may be of importance for the pathogenesis of the allergen induced late phase asthmatic reaction.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3774850     DOI: 10.1016/0031-6989(86)90039-1

Source DB:  PubMed          Journal:  Pharmacol Res Commun        ISSN: 0031-6989


  13 in total

Review 1.  Oxidant stress in asthma.

Authors:  R Dworski
Journal:  Thorax       Date:  2000-10       Impact factor: 9.139

Review 2.  The role of eosinophils in asthma.

Authors:  C Kroegel
Journal:  Lung       Date:  1990       Impact factor: 2.584

Review 3.  PAF. A review of its effects, antagonists and possible future clinical implications (Part II).

Authors:  M Koltai; D Hosford; P Guinot; A Esanu; P Braquet
Journal:  Drugs       Date:  1991-08       Impact factor: 9.546

4.  Effect of the selective PAF antagonist SM-10661 on an asthmatic model. 2. Effect on antigen-induced dual asthmatic response and infiltration of leukocytes into airways in actively sensitized conscious guinea pigs.

Authors:  T Sugasawa; N Imanishi; S Morooka
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

5.  Priming effect of platelet activating factor on leukotriene C4 from stimulated eosinophils of asthmatic patients.

Authors:  K Shindo; K Koide; Y Hirai; M Sumitomo; M Fukumura
Journal:  Thorax       Date:  1996-02       Impact factor: 9.139

6.  Density heterogeneity of eosinophil leucocytes: induction of hypodense eosinophils by platelet-activating factor.

Authors:  T Yukawa; C Kroegel; P Evans; T Fukuda; K F Chung; P J Barnes
Journal:  Immunology       Date:  1989-09       Impact factor: 7.397

7.  Inhibition of chemiluminescence in granulocytes and alveolar macrophages by azelastine.

Authors:  J Schmidt; B Kaufmann; R Lindstaedt; I Szelenyi
Journal:  Agents Actions       Date:  1990-11

8.  Effects of theophylline and rolipram on leukotriene C4 (LTC4) synthesis and chemotaxis of human eosinophils from normal and atopic subjects.

Authors:  H Tenor; A Hatzelmann; M K Church; C Schudt; J K Shute
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

9.  Participation of the cysteinyl leukotrienes in the acute bronchoconstrictor response to inhaled platelet activating factor in man.

Authors:  D A Spencer; J M Evans; S E Green; P J Piper; J F Costello
Journal:  Thorax       Date:  1991-06       Impact factor: 9.139

10.  Effects of REV 5901, a 5-lipoxygenase inhibitor and leukotriene antagonist, on pulmonary responses to platelet activating factor in the guinea-pig.

Authors:  G Anderson; M Fennessy
Journal:  Br J Pharmacol       Date:  1988-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.